{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:20:07Z","timestamp":1792894807077,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2020\/133\/Startup\/08"],"award-info":[{"award-number":["NUHSRO\/2020\/133\/Startup\/08"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy with immune checkpoint blockade (ICB) for glioblastoma (GBM) is promising but its clinical efficacy is seriously challenged by the blood-tumor barrier (BTB) and immunosuppressive tumor microenvironment. Here, anti-programmed death-ligand 1 antibodies (aPD-L1) are loaded into a redox-responsive micelle and the ICB efficacy is further amplified by paclitaxel (PTX)-induced immunogenic cell death (ICD) via a co-encapsulation approach for the reinvigoration of local anti-GBM immune responses. Consequently, the micelles cross the BTB and are retained in the reductive tumor microenvironment without altering the bioactivity of aPD-L1. The ICB efficacy is enhanced by the aPD-L1 and PTX combination with suppression of primary and recurrent GBM, accumulation of cytotoxic T lymphocytes, and induction of long-lasting immunological memory in the orthotopic GBM-bearing mice. The co-encapsulation approach facilitating efficient antibody delivery and combining with chemotherapeutic agent-induced ICD demonstrate that the chemo-immunotherapy might reprogram local immunity to empower immunotherapy against GBM.<\/jats:p>","DOI":"10.1038\/s41467-024-44963-3","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T14:02:33Z","timestamp":1707228153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-1254","authenticated-orcid":false,"given":"Zhiqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-2487","authenticated-orcid":false,"given":"Yonger","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-7865","authenticated-orcid":false,"given":"Shenghong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"44963_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","volume":"392","author":"S Lapointe","year":"2018","unstructured":"Lapointe, S., Perry, A. & Butowski, N. A. Primary brain tumours in adults. Lancet 392, 432\u2013446 (2018).","journal-title":"Lancet"},{"key":"44963_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","volume":"16","author":"K Aldape","year":"2019","unstructured":"Aldape, K. et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 16, 509\u2013520 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"44963_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye, A. & Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol. Oncol. 12, 1\u201313 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"44963_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang, X. et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol. Cancer 18, 1\u201317 (2019).","journal-title":"Mol. Cancer"},{"key":"44963_CR5","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"44963_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non\u2013small-cell lung cancer. N. Engl. J. Med. 372, 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"key":"44963_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3389\/fphar.2018.01503","volume":"9","author":"RQ Chen","year":"2019","unstructured":"Chen, R. Q., Liu, F., Qiu, X. Y. & Chen, X. Q. The prognostic and therapeutic value of PD-L1 in glioma. Front. Pharmacol. 9, 1503 (2019).","journal-title":"Front. Pharmacol."},{"key":"44963_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nan.12767","volume":"48","author":"G Vimalathas","year":"2022","unstructured":"Vimalathas, G. & Kristensen, B. W. Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. Neuropathol. Appl. Neurobiol. 48, 1\u201327 (2022).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"44963_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0586-5","volume":"19","author":"AC Tan","year":"2017","unstructured":"Tan, A. C., Heimberger, A. B. & Khasraw, M. Immune checkpoint inhibitors in gliomas. Curr. Oncol. Rep. 19, 23 (2017).","journal-title":"Curr. Oncol. Rep."},{"key":"44963_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.578877","volume":"11","author":"Y Qi","year":"2020","unstructured":"Qi, Y., Liu, B., Sun, Q., Xiong, X. & Chen, Q. Immune checkpoint targeted therapy in glioma: status and hopes. Front. Immunol. 11, 1\u201312 (2020).","journal-title":"Front. Immunol."},{"key":"44963_CR11","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","volume":"8","author":"AC Filley","year":"2017","unstructured":"Filley, A. C., Henriquez, M. & Dey, M. Recurrent glioma clinical trial, CheckMate-143: The game is not over yet. Oncotarget 8, 91779\u201391794 (2017).","journal-title":"Oncotarget"},{"key":"44963_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"44963_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson, J. H., Gunn, M. D., Fecci, P. E. & Ashley, D. M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer 20, 12\u201325 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"44963_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"44963_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.585616","volume":"11","author":"T Daubon","year":"2020","unstructured":"Daubon, T., Hemadou, A., Romero Garmendia, I. & Saleh, M. Glioblastoma immune landscape and the potential of new immunotherapies. Front. Immunol. 11, 1\u201317 (2020).","journal-title":"Front. Immunol."},{"key":"44963_CR16","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","volume":"23","author":"JV Heymach","year":"2022","unstructured":"Heymach, J. V. et al. Design and rationale for a phase iii, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages ii and iii non-small-cell lung cancer: The AEGEAN Tr. Clin. Lung Cancer 23, e247\u2013e251 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"44963_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol. 7, 522\u2013532 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"44963_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang, N. J. et al. Efficacy and safety of autologous dendritic cell\u2013based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 8, 546 (2022).","journal-title":"JAMA Oncol."},{"key":"44963_CR19","doi-asserted-by":"publisher","first-page":"e003190","DOI":"10.1136\/jitc-2021-003190","volume":"10","author":"L Rob","year":"2022","unstructured":"Rob, L. et al. Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J. Immunother. Cancer 10, e003190 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"44963_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24902-2","volume":"12","author":"J Qi","year":"2021","unstructured":"Qi, J. et al. Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles. Nat. Commun. 12, 4755 (2021).","journal-title":"Nat. Commun."},{"key":"44963_CR21","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/jcmm.14356","volume":"23","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J. Cell. Mol. Med. 23, 4854\u20134865 (2019).","journal-title":"J. Cell. Mol. Med."},{"key":"44963_CR22","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.1021\/acsnano.0c03386","volume":"14","author":"H Kinoh","year":"2020","unstructured":"Kinoh, H. et al. Translational nanomedicine boosts anti-pd1 therapy to eradicate orthotopic pten-negative glioblastoma. ACS Nano 14, 10127\u201310140 (2020).","journal-title":"ACS Nano"},{"key":"44963_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"44963_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2017.06.006","volume":"114","author":"JG Lyon","year":"2017","unstructured":"Lyon, J. G. et al. Engineering challenges for brain tumor immunotherapy. Adv. Drug Deliv. Rev. 114, 19\u201332 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"44963_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat. Rev. Drug Discov. 20, 362\u2013383 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"44963_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11719-3","volume":"10","author":"A Galstyan","year":"2019","unstructured":"Galstyan, A. et al. Blood\u2013brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat. Commun. 10, 1\u201313 (2019).","journal-title":"Nat. Commun."},{"key":"44963_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 8, 1\u201313 (2016).","journal-title":"Sci. Transl. Med."},{"key":"44963_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin, J. D., Cabral, H., Stylianopoulos, T. & Jain, R. K. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17, 251\u2013266 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"44963_CR29","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41563-021-01047-7","volume":"20","author":"I de L\u00e1zaro","year":"2021","unstructured":"de L\u00e1zaro, I. & Mooney, D. J. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat. Mater. 20, 1469\u20131479 (2021).","journal-title":"Nat. Mater."},{"key":"44963_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s40820-020-00482-6","volume":"12","author":"W Mu","year":"2020","unstructured":"Mu, W., Chu, Q., Liu, Y. & Zhang, N. A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano-Micro Lett. 12, 142 (2020).","journal-title":"Nano-Micro Lett."},{"key":"44963_CR31","doi-asserted-by":"publisher","first-page":"121376","DOI":"10.1016\/j.biomaterials.2022.121376","volume":"281","author":"P Yuan","year":"2022","unstructured":"Yuan, P. et al. Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules. Biomaterials 281, 121376 (2022).","journal-title":"Biomaterials"},{"key":"44963_CR32","doi-asserted-by":"publisher","first-page":"119865","DOI":"10.1016\/j.ijpharm.2020.119865","volume":"589","author":"P Song","year":"2020","unstructured":"Song, P., Zhao, X. & Xiao, S. Application prospect of peptide-modified nano targeting drug delivery system combined with PD-1\/PD-L1 based immune checkpoint blockade in glioblastoma. Int. J. Pharm. 589, 119865 (2020).","journal-title":"Int. J. Pharm."},{"key":"44963_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O Van Tellingen","year":"2015","unstructured":"Van Tellingen, O. et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 19, 1\u201312 (2015).","journal-title":"Drug Resist. Updat."},{"key":"44963_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bcp.2011.11.016","volume":"83","author":"DS Backos","year":"2012","unstructured":"Backos, D. S., Franklin, C. C. & Reigan, P. The role of glutathione in brain tumor drug resistance. Biochem. Pharmacol. 83, 1005\u20131012 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"44963_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3109\/1354750X.2012.715672","volume":"17","author":"MP Gamcsik","year":"2012","unstructured":"Gamcsik, M. P., Kasibhatla, M. S., Teeter, S. D. & Colvin, O. M. Glutathione levels in human tumors. Biomarkers 17, 671\u2013691 (2012).","journal-title":"Biomarkers"},{"key":"44963_CR36","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.18632\/oncotarget.2266","volume":"5","author":"O Kepp","year":"2014","unstructured":"Kepp, O., Senovilla, L. & Kroemer, G. Immunogenic cell death inducers as anticancer agents. Oncotarget 5, 5190\u20135191 (2014).","journal-title":"Oncotarget"},{"key":"44963_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000337","volume":"8","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer 8, 1\u201322 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"44963_CR38","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1039\/C9CS00271E","volume":"48","author":"Q Chen","year":"2019","unstructured":"Chen, Q., Chen, M. & Liu, Z. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chem. Soc. Rev. 48, 5506\u20135526 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"44963_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/acsnano.0c07132","volume":"15","author":"X Ling","year":"2021","unstructured":"Ling, X. et al. Sequential Treatment of Bioresponsive Nanoparticles Elicits Antiangiogenesis and Apoptosis and Synergizes with a CD40 Agonist for Antitumor Immunity. ACS Nano 15, 765\u2013780 (2021).","journal-title":"ACS Nano"},{"key":"44963_CR40","doi-asserted-by":"publisher","first-page":"119491","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie, J., Shen, Z., Anraku, Y., Kataoka, K. & Chen, X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 224, 119491 (2019).","journal-title":"Biomaterials"},{"key":"44963_CR41","doi-asserted-by":"publisher","first-page":"13227","DOI":"10.1073\/pnas.1609397113","volume":"113","author":"K Kirschbaum","year":"2016","unstructured":"Kirschbaum, K. et al. In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. Proc. Natl Acad. Sci. USA 113, 13227\u201313232 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"44963_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36321-6","volume":"14","author":"V Turco","year":"2023","unstructured":"Turco, V. et al. T cell-independent eradication of experimental glioma by intravenous TLR7\/8-agonist-loaded nanoparticles. Nat. Commun. 14, 771 (2023).","journal-title":"Nat. Commun."},{"key":"44963_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"44963_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7301","volume":"6","author":"I Kinjyo","year":"2015","unstructured":"Kinjyo, I. et al. Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation. Nat. Commun. 6, 6301 (2015).","journal-title":"Nat. Commun."},{"key":"44963_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.1048758","volume":"13","author":"KR Plunkett","year":"2022","unstructured":"Plunkett, K. R. et al. Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. Front. Immunol. 13, 1\u201317 (2022).","journal-title":"Front. Immunol."},{"key":"44963_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria, J. N. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro. Oncol. 20, 184\u2013191 (2018).","journal-title":"Neuro. Oncol."},{"key":"44963_CR47","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","volume":"24","author":"KI Woroniecka","year":"2018","unstructured":"Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A. & Fecci, P. E. T-Cell dysfunction in glioblastoma: Applying a new framework. Clin. Cancer Res. 24, 3792\u20133802 (2018).","journal-title":"Clin. Cancer Res."},{"key":"44963_CR48","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka, K. et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 4175\u20134186 (2018).","journal-title":"Clin. Cancer Res."},{"key":"44963_CR49","first-page":"1","volume":"6","author":"L Bezu","year":"2015","unstructured":"Bezu, L. et al. Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol. 6, 1\u201311 (2015).","journal-title":"Front. Immunol."},{"key":"44963_CR50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7150\/thno.17237","volume":"7","author":"C Guo","year":"2017","unstructured":"Guo, C. et al. Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models. Theranostics 7, 775\u2013788 (2017).","journal-title":"Theranostics"},{"key":"44963_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2016.07.022","volume":"238","author":"B Zhang","year":"2016","unstructured":"Zhang, B. et al. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J. Control. Release 238, 10\u201321 (2016).","journal-title":"J. Control. Release"},{"key":"44963_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00195","volume":"9","author":"JM Pacheco","year":"2019","unstructured":"Pacheco, J. M., Ross Camidge, D., Doebele, R. C. & Schenk, E. A changing of the guard: Immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Front. Oncol. 9, 1\u201313 (2019).","journal-title":"Front. Oncol."},{"key":"44963_CR53","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","volume":"170","author":"JBAG Haanen","year":"2017","unstructured":"Haanen, J. B. A. G. Converting cold into hot tumors by combining immunotherapies. Cell 170, 1055\u20131056 (2017).","journal-title":"Cell"},{"key":"44963_CR54","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/cncr.33378","volume":"127","author":"DA Reardon","year":"2021","unstructured":"Reardon, D. A. et al. Treatment with pembrolizumab in programmed death ligand 1\u2013positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127, 1620\u20131629 (2021).","journal-title":"Cancer"},{"key":"44963_CR55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend, A. M. et al. Repeated blood\u2013brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24, 509\u2013522 (2023).","journal-title":"Lancet Oncol."},{"key":"44963_CR56","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4143\/crt.2022.1436","volume":"55","author":"SH Nam","year":"2023","unstructured":"Nam, S. H., Kim, Y. M., Lee, S.-W. & Lee, Y.-J. Safety and tolerability of weekly genexol-pm, a cremophor-free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic cancer: a phase i study. Cancer Res. Treat. 55, 1346\u20131354 (2023).","journal-title":"Cancer Res. Treat."},{"key":"44963_CR57","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660.e17 (2020).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44963-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T18:05:51Z","timestamp":1707501951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44963-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44963"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-44963-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1118"}}